Emcure Pharma Q1 FY27 Earnings Call — Analysis (NSE: EMCURE)
Emcure Q1 FY27 delivers broad-based 22.8% revenue growth and 50 bps EBITDA margin expansion; India returns to double-digit growth and international surges 34.2%.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹2,580 Cr ( +22.8% YoY ) . New guidance — FY27 fy27 revenue growth low to mid-teen . New story: Domestic recovery and Zuventus turnaround .
Results
Revenue ₹2,580 Cr +22.8% YoY; EBITDA ₹508 Cr +25.8% YoY; EBITDA margin 19.7% (+50 bps); PAT ₹292 Cr +36.2% YoY (CEO)/+35.4% YoY (CFO).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹2,580 Cr | +22.8% | yoy · Q1FY27 |
| EBITDA | ₹508 Cr | +25.8% | yoy · Q1FY27 |
| EBITDA margin | 19.7% | +50 bps | yoy · Q1FY27 |
| PAT | ₹292 Cr | +36.2% | yoy · Q1FY27 · CEO stated 36.2%; CFO stated 35.4% |
| Domestic revenue | ₹1,095 Cr | +10.2% | yoy · Q1FY27 |
| International revenue | ₹1,485 Cr | +34.2% | yoy · Q1FY27 |
| Europe revenue | ₹537 Cr | +32.8% | yoy · Q1FY27 |
| Canada revenue | ₹427 Cr | +24.6% | yoy · Q1FY27 |
| Rest of World revenue | ₹522 Cr | +44.8% | yoy · Q1FY27 |
| Gross margin | 58.4% | −declined | yoy · Q1FY27 · decline led by product/geography mix |
| Gross debt | ₹1,291 Cr | point_in_time · Jun-26 · as on 30 June 2026 | |
| Net debt | ₹1,103 Cr | point_in_time · Jun-26 · as on 30 June 2026 |
Guidance
FY27 low-to-mid teen revenue growth (comfortable at higher end), 70-100 bps EBITDA margin expansion, gross margin ~59%, and net cash by FY28.
What management committed to
- [Emcure] will deliver low to mid-teen revenue growth in FY27. — low to mid-teen, FY27
- [Emcure] is comfortable being at the higher end of the low to mid-teen revenue growth guidance for FY27. — higher end of low to mid-teen, FY27
- [Emcure] will achieve 70 to 100 basis points of EBITDA margin expansion in FY27. — 70 to 100 basis points, FY27
- [Emcure]'s full-year gross margin for FY27 will be around 59%. — around 59%, FY27
- [Emcure]'s R&D spend as a percentage of revenue will be between 4% and 5% in FY27. — 4% to 5%, FY27
- [Emcure]'s net debt will be close to ₹1,450 crore by the end of Q2 FY27 (September 2026). — close to around ₹1,450 crore, Q2FY27
- [Emcure] will become net cash by the end of FY28. — FY28
- [Emcure]'s domestic revenue growth in Q2 FY27 will be in line with the Indian Pharmaceutical Market (IPM) growth. — in line with the industry, Q2FY27
- [Emcure]'s domestic revenue growth in the second half of FY27 will be faster than IPM growth. — faster than the industry growth, H2FY27
- ARV business will contribute 50-55% of [Emcure]'s Rest of World (ROW) revenue in FY27. — 50% to 55%, FY27
- [Emcure] will file for semaglutide in Canada within the current quarter (Q2 FY27), i.e., by September 2026. — Q2FY27
- [Emcure]'s working capital will return to normal levels in Q2 FY27 after a temporary increase in Q1. — Q2FY27
Key themes
International momentum and domestic recovery with margin expansion
How the narrative shifted
- Domestic recovery and Zuventus turnaround: Management positions the domestic business as having completed the Zuventus consolidation phase and now entering acceleration, with India growth expected to return to industry parity and then outperform.
- International scale-up as growth engine: International growth is robust across Europe, Canada, and ROW, driven by ARV tenders, Amphotericin ramp, and broad-based portfolio; management signals higher top-line guidance on this strength.
- Biosimilars and Gennova integration: Full ownership of Gennova and appointment of Samit Mehta as its CEO underscore a sharpened focus on biologics and biosimilars as a long-term growth vertical.
- In-licensing and portfolio complementarity: Deals with Sanofi, Roche, Novo Nordisk (Poviztra) and new licensing with MSD/ICMR expand therapy presence and prescriber reach, part of the strategy to improve market coverage and brand depth.
- Margin resilience despite gross margin mix pressure: Management acknowledges gross margin dilution from faster-growing international B2B segments but highlights EBITDA margin expansion through operating leverage and cost control, maintaining 70-100 bps expansion target.
- Currency tailwind and geopolitical resilience: 6-7% constant currency tailwind noted at company level; management underscores resilience despite geopolitical uncertainties, but does not depend on external environment for guidance.
Operational commentary
- Emcure acquired remaining 12.05% minority stake in Gennova, making it a 100% subsidiary to sharpen biosimilars focus; Samit Mehta appointed CEO of Gennova.
- Samit Mehta becomes COO of Emcure with broader oversight of R&D, manufacturing, and licensing; Satish Mehta to take additional role of Chairman post-AGM.
- Zuventus restructuring: stability achieved, consolidation nearly complete, now moving to acceleration; domestic organic growth expected to rebound.
- ARV segment very strong in ROW (2/3 of ROW revenue in Q1); full-year ARV share expected 50-55%; MSD voluntary license signed for monthly oral HIV PrEP alimatravir (late-stage).
- ICMR licensed novel anti-HPV NCE to Emcure for cervical intraepithelial neoplasia, strengthening women's health portfolio.
- Received 15+ product approvals across developed and emerging markets in Q1, supporting future international growth.
- Poviztra (semaglutide, Novo Nordisk) seeing month-on-month traction; recently approved for MASH, enabling hepatologist coverage.
- Consumer wellness subsidiary Emcure Wellness gaining early traction; Bitter Drops showing scalable growth signals.
- UK acquisition Mantra contributing; Canada semaglutide filing planned in the coming months (second wave due to global development coordination).
Analyst Q&A
Q. Question on domestic growth outlook and Zuventus restructuring progress.
CEO Satish Mehta outlined three phases—stability, consolidation, acceleration—stating stability and consolidation are done, now moving to acceleration; Piyush Nahar added domestic growth will be in line with industry from Q2 and faster in H2.
Q. Reason for slower domestic organic growth and when it will reach market parity.
Vikas Thapar explained organic growth was impacted by Zuventus consolidation, expects full-year organic growth at par or faster than IPM; Piyush Nahar quantified Q1 organic excluding in-licensed at ~6-7%.
Q. Revised timelines for semaglutide launch in Canada and Quebec following Dr. Reddy's product recall.
Piyush Nahar stated they will defer to Dr. Reddy's on the timeline and launch depends on supplies from Reddy's; no specific date given.
Q. Working capital increase and net debt trajectory.
CFO Taj Shaikh said working capital uptick in Q1 has stabilized in July, will normalize in Q2; net debt post acquisitions will be ~₹1,450 Cr and net cash by FY28.
Q. Gross margin decline despite currency tailwind and outlook.
Piyush Nahar and Vikas Thapar attributed lower GM to product/business mix (Europe, ARV) with higher EBITDA contribution; FY27 GM guided to ~59%, with top-line likely at higher end of guidance.
Research and educational content only. Not investment advice.